The European Commission (EC) granted marketing authorisation for Darzalex in combination with bortezomib, thalidomide and dexamethasone (VTd) for multiple myeloma patients.
List view / Grid view
Filter the results
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
A treatment for amyloidosis has been pulled from clinical trials after failing to reach endpoints.